Market Overview

UPDATE: Canaccord Genuity Reduces PT to $77 on Warner Chilcott

Related WCRX
Actavis, Warner Chilcott Receive FTC Clearance for Actavis' Proposed Acquisition of Warner Chilcott
Top 4 Mid-Cap Stocks In The Drug Manufacturers-Other Industry With The Highest Profit Margin

Canaccord Genuity reiterated its Buy rating on Warner Chilcott (NASDAQ: WCRX) but reduced its price target from $25 to $18 following the company's conclusion of a strategic review.

Canaccord Genuity said, "WCRX announced it has completed its strategic review with the result being a return of capital: another special dividend, a new ongoing dividend and share buyback renewal. We expect initial reaction to be disappointment at a lack of company sale or deal by WCRX, which could lead to some weakness with the upside case removed."

Warner Chilcott closed at $17.77 on Tuesday.

Latest Ratings for WCRX

Jul 2013Leerink SwannUpgradesMarket PerformOutperform
Jun 2013JefferiesDowngradesBuyHold
May 2013Leerink SwannDowngradesOutperformMarket Perform

View More Analyst Ratings for WCRX
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Pre-Market Outlook Analyst Ratings


Related Articles (WCRX)

View Comments and Join the Discussion!